Pharmaceutical

GSK’s Omjjara gains approval in Japan for myelofibrosis treatment

GSK has received approval from the Japan's Ministry of Health, Labour and Welfare (MHLW) for Omjjara to treat patients with myelofibrosis.

Jun 26, 2024 - 04:00
GSK’s Omjjara gains approval in Japan for myelofibrosis treatment
GSK has received approval from the Japan's Ministry of Health, Labour and Welfare (MHLW) for Omjjara to treat patients with myelofibrosis.
Read the original article

Tags:

Previous Article

Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine

Next Article

Novo Nordisk invests $4.1bn in manufacturing facility in NC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Tacalyx extends seed funding round to raise over €14m

Tacalyx extends seed funding round to raise over €14m

Jun 12, 2024

AI and stable funding environments are catalysts for biotech assets

AI and stable funding environments are catalysts for bi...

Jun 28, 2024

FDA issues CRL to Orexo’s NDA for opioid overdose medication

FDA issues CRL to Orexo’s NDA for opioid overdose medic...

Jul 18, 2024